Aequus Pharmaceuticals (TSE:AQS) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Aequus Pharmaceuticals Inc. reports a record-breaking sales quarter for Zimed® PF, the first preservative-free prostaglandin analog for glaucoma in Canada, signaling strong clinician adoption and patient benefit. As a specialty pharmaceutical company, Aequus focuses on developing and commercializing differentiated products in areas such as Ophthalmology and Optometry. Zimed® PF, approved by Health Canada in December 2022, addresses the needs of glaucoma and ocular hypertension patients, offering a preservative-free treatment option.
For further insights into TSE:AQS stock, check out TipRanks’ Stock Analysis page.